Fibrodysplasia Ossificans Progressiva Market Forecast 2032: FDA Approvals, Clinical Trials, & Companies By Delveinsight


(MENAFN- EIN Presswire)

Fibrodysplasia Ossificans Progressiva market Forecast

The Fibrodysplasia Ossificans Progressiva market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.

ALBANY, NEW YORK, UNITED STATES, July 10, 2024 /EINPresswire / -- DelveInsight's“Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Fibrodysplasia Ossificans Progressiva, historical and forecasted epidemiology as well as the Fibrodysplasia Ossificans Progressiva market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Fibrodysplasia Ossificans Progressiva market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Fibrodysplasia Ossificans Progressiva market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fibrodysplasia Ossificans Progressiva Market Forecast

Some of the key facts of the Fibrodysplasia Ossificans Progressiva Market Report:
. The Fibrodysplasia Ossificans Progressiva market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
. In June 2023, Ipsen revealed that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US FDA has supported the investigational drug palovarotene as a viable treatment option with a favorable risk-benefit profile for individuals affected by the extremely rare bone disorder, FOP. Currently, the FDA is evaluating the New Drug Application (NDA) for palovarotene, and a decision is expected by August 16, 2023. Should it receive approval, palovarotene would mark the inaugural treatment available in the US for FOP.
. In 2022, the collective diagnosed prevalent instances of Fibrodysplasia ossificans progressiva across the seven major markets (7MM) were approximately 690 cases. Projections suggest a rise in these numbers throughout the forecast period.
. In the seven major markets (7MM), the United States recorded the highest number of diagnosed prevalent cases, approximately 300, for Fibrodysplasia ossificans progressiva in 2022.
. According to a study by Moira et al., the prevalence of Fibrodysplasia Ossificans Progressiva is approximately 0.65 per million in North America, 0.47 per million in Western Europe, and 0.27 per million in Latin America to 0.05 per million in Africa and nearly 0.04 per million in the Asia-Pacific region.
. Key Fibrodysplasia Ossificans Progressiva Companies: Ipsen, Regeneron Pharmaceutical, Biocryst,, and others
. Key Fibrodysplasia Ossificans Progressiva Therapies: Palovarotene, Garetosmab, BCX9250, and others
. The Fibrodysplasia Ossificans Progressiva epidemiology based on gender analyzed that females are more prevalent for Fibrodysplasia Ossificans Progressiva rather than males. It has been found that 54% females and 46% males are affected with Fibrodysplasia Ossificans Progressiva
. The Fibrodysplasia Ossificans Progressiva epidemiology based on gender analyzed that females are more prevalent for Fibrodysplasia Ossificans Progressiva rather than males. It has been found that 54% females and 46% males are affected with Fibrodysplasia Ossificans Progressiva

Fibrodysplasia Ossificans Progressiva Overview
Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling genetic disorder characterized by the abnormal development of bone in muscles, tendons, ligaments, and other connective tissues. This process, known as heterotopic ossification, progressively restricts movement by forming a second skeleton that imprisons the body. Fibrodysplasia ossificans progressiva is caused by mutations in the ACVR1 gene, which encodes a receptor involved in the bone morphogenetic protein (BMP) signaling pathway, leading to excessive bone formation.
Symptoms often begin in early childhood, typically with malformations of the big toes present at birth. Flare-ups of painful soft tissue swellings occur, which eventually turn into bone. These episodes can be triggered spontaneously or by trauma, such as falls, intramuscular injections, or surgical procedures.
Diagnosis is primarily clinical, based on characteristic symptoms and confirmed by genetic testing. Imaging studies, such as X-rays, can also reveal the extent of heterotopic bone formation.
Currently, there is no cure for Fibrodysplasia ossificans progressiva. Management focuses on preventing flare-ups, managing symptoms, and maintaining mobility. Avoiding trauma, using medications like corticosteroids during flare-ups, and supportive care from a multidisciplinary team can help improve quality of life. Research is ongoing to develop targeted therapies that can inhibit the abnormal bone formation process, offering hope for better management in the future.

Get a Free sample for the Fibrodysplasia Ossificans Progressiva Market Report:

Fibrodysplasia Ossificans Progressiva Market
The dynamics of the Fibrodysplasia Ossificans Progressiva market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

Fibrodysplasia Ossificans Progressiva Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fibrodysplasia Ossificans Progressiva Epidemiology Segmentation:
The Fibrodysplasia Ossificans Progressiva market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
. Total Prevalence of Fibrodysplasia Ossificans Progressiva
. Prevalent Cases of Fibrodysplasia Ossificans Progressiva by severity
. Gender-specific Prevalence of Fibrodysplasia Ossificans Progressiva
. Diagnosed Cases of Episodic and Chronic Fibrodysplasia Ossificans Progressiva

Download the report to understand which factors are driving Fibrodysplasia Ossificans Progressiva epidemiology trends @ Fibrodysplasia Ossificans Progressiva Prevalence

Fibrodysplasia Ossificans Progressiva Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fibrodysplasia Ossificans Progressiva market or expected to get launched during the study period. The analysis covers Fibrodysplasia Ossificans Progressiva market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Fibrodysplasia Ossificans Progressiva Pipeline
Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Fibrodysplasia Ossificans Progressiva treatment, visit @

Fibrodysplasia Ossificans Progressiva Therapies and Key Companies
. Palovarotene: Ipsen
. Garetosmab: Regeneron Pharmaceutical
. Biocryst: BCX9250

Scope of the Fibrodysplasia Ossificans Progressiva Market Report
. Study Period: 2019–2032
. Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
. Key Fibrodysplasia Ossificans Progressiva Companies: Ipsen, Regeneron Pharmaceutical, Biocryst, and others
. Key Fibrodysplasia Ossificans Progressiva Therapies: Palovarotene, Garetosmab, BCX9250, and others
. Fibrodysplasia Ossificans Progressiva Therapeutic Assessment: Fibrodysplasia Ossificans Progressiva current marketed and Fibrodysplasia Ossificans Progressiva emerging therapies
. Fibrodysplasia Ossificans Progressiva Market Dynamics: Fibrodysplasia Ossificans Progressiva market drivers and Fibrodysplasia Ossificans Progressiva market barriers
. Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
. Fibrodysplasia Ossificans Progressiva Unmet Needs, KOL's views, Analyst's views, FibrodysplasiaOssificans Progressiva Market Access and Reimbursement

Discover more about therapies set to grab major Fibrodysplasia Ossificans Progressiva market share @ Fibrodysplasia Ossificans Progressiva Treatment Market

Table of Contents
1. Fibrodysplasia Ossificans Progressiva Market Report Introduction
2. Executive Summary for Fibrodysplasia Ossificans Progressiva
3. SWOT analysis of Fibrodysplasia Ossificans Progressiva
4. Fibrodysplasia Ossificans Progressiva Patient Share (%) Overview at a Glance
5. Fibrodysplasia Ossificans Progressiva Market Overview at a Glance
6. Fibrodysplasia Ossificans Progressiva Disease Background and Overview
7. Fibrodysplasia Ossificans Progressiva Epidemiology and Patient Population
8. Country-Specific Patient Population of Fibrodysplasia Ossificans Progressiva
9. Fibrodysplasia Ossificans Progressiva Current Treatment and Medical Practices
10. Fibrodysplasia Ossificans Progressiva Unmet Needs
11. Fibrodysplasia Ossificans Progressiva Emerging Therapies
12. Fibrodysplasia Ossificans Progressiva Market Outlook
13. Country-Wise Fibrodysplasia Ossificans Progressiva Market Analysis (2020–2034)
14. Fibrodysplasia Ossificans Progressiva Market Access and Reimbursement of Therapies
15. Fibrodysplasia Ossificans Progressiva Market Drivers
16. Fibrodysplasia Ossificans Progressiva Market Barriers
17. Fibrodysplasia Ossificans Progressiva Appendix
18. Fibrodysplasia Ossificans Progressiva Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Ankit Nigam
DelveInsight Business Research
+1 469-945-7679
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
Other

MENAFN10072024003118003196ID1108427250


EIN Presswire

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.